The in vitro activity of LY 146032, a cyclic lipopeptide antibiotic belonging to the class of agents designated A21978C, was compared with those of vancomycin, cefpirome, cefotaxime, and clindamycin against selected gram-positive bacteria. The new drug inhibited all staphylococcal isolates, including methicillin-resistant strains, at concentrations of s1.0 ,ug/mi. The activity of LY 146032 was comparable to that of vancomycin against most streptococci, but the latter demonstrated greater potency against Streptococcus faecium and penicillin-resistant strains of pneumococci and viridans group streptococci. LY 146032 was markedly less active than vancomycin against Listeria monocytogenes (MICs for 90% of strains tested, 16 and 1.0 ,ug/ml, respectively). The activity of LY 146032 was enhanced as the concentration of calcium in the test medium was increased. MBCs were within eightfold of the MIC for each of 12 strains tested. In a rat model of enterococcal endocarditis, the administration of LY 146032 resulted in increased survival and a reduction in the bacterial titer within cardiac vegetations compared with untreated control animals. This study examined the in vitro activity of LY 146032 against gram-positive bacteria compared with those of van The animals with negative blood cultures at this stage were excluded from the study. Antibiotics were administered by continuous infusion with a Sage 352 syringe pump (Orion Research, Inc., Cambridge, Mass.), beginning within 4 h of line insertion. LY 146032 or vancomycin was given at doses of 100 or 50 mg/kg (body weight) per day, respectively, to achieve mean concentrations in serum of 4 to 8 times the MIC of each drug. A series of untreated animals served as controls once preliminary studies indicated that the infusion of saline alone did not influence the course of endocarditis. Antibiotic levels in serum were determined by microbiological assay (5) using a test strain of "Bacillus globigii" for vancomycin and "Sarcina luteus" for LY 146032. The latter assay detected serum levels of .1 jxg/ml and was reproducible to ±7% in the range of concentrations achieved in vivo.
After 5 days of antibiotic therapy, blood cultures were obtained and the animals were sacrificed. Vegetations were excised, weighed, and homogenized in a tissue grinder with sterile saline for subsequent colony counts. Statistical analysis was performed by using the x2 test with Yates' correction or Student's t test for discrete or continuous variables, respectively.
RESULTS
Susceptibility studies. The results of in vitro agar dilution susceptibility studies are shown in Table 1 . LY 146032 was slightly more active than vancomycin against both methi- The in vitro activity of LY 146032 against representative strains of several bacterial species was enhanced when broth medium (normal calcium concentration, <4 mg/liter [1] ) was supplemented with calcium chloride to physiologic concentrations of the cation ( Table 2 ). The activity of the drug against an S. faecalis strain increased in a continuous fashion with increasing concentrations of calcium to the highest level tested, with MICs ranging from 128 jig/ml at calcium concentrations of _6.25 mg/liter to 4 ,ug/ml when calcium was added at 100 mg/liter. Of note is the fact that the broth dilution MICs shown in Table 2 (for calciumsupplemented media) were higher than the corresponding agar dilution MICs. Detailed studies with four isolates indicated that broth dilution MICs obtained with an inoculum of 106 CFU/ml were two-to fourfold higher than those obtained with an inoculum of 104 CFU/ml. Inherent technical differences between the two techniques (8) may also have contributed to the higher values derived in the tube dilution study. It was also apparent that LY 146032 was bactericidal at concentrations .8 times the MIC against each of the isolates tested, including all four strains of S. faecalis ( 
DISCUSSION
The in vitro activity of LY 146032 against the grampositive bacteria tested was found to be generally comparable to that of the previously described lipopeptide, A21978C1, as reported in an earlier study (1) . Although the new analog was somewhat less active than A21978C1 against S. faecalis (MIC for 90% of strains tested [MIC90], 2 and 1 ,ug/ml, respectively) and S. faecium (MIC90, 8 and 2 ,ug/ml, respectively), these results may be offset by the superior therapeutic index of LY 146032 in initial animal studies (M. DeBono et al., 24th ICAAC, abstr. no. 1077, 1984). The new lipopeptide antibiotic was more active than vancomycin against staphylococci, including methicillin-resistant strains, and some streptococci; however, vancomycin exhibited greater potency against penicillin-resistant pneumococci and viridans group streptococci, as well as L. monocytogenes and some enterococci.
As seen with A21978C1, the in vitro activity of LY 146032 demonstrated a striking dependence on calcium concentration in the growth medium (1) . The mechanism by which this occurs has not been established. Like A21978C1, the antibacterial properties of the new lipopeptide appear to result, at least in part, from its ability to inhibit cell wall peptidoglycan synthesis (N. Allen, W. Alborn, Jr., J. Hobbs, Jr., and H. Percifield, 24th ICAAC, abstr. no. 1081, 1984) .
The observation that LY 146032 was bactericidal at concentrations near the MIC against all five enterococci tested is of interest, given the requirement that serious enterococcal infections be treated with combinations of a cell-wall-active agent and an aminoglycoside (6) . Our animal model of enterococcal endocarditis confirmed the significant activity of LY 146032 under physiologic conditions, which resulted in a 3-log10 reduction in bacterial titers within cardiac vegetations (in comparison with controls) after only 5 days of therapy. Preliminary studies by others using a different model indicated that more prolonged courses of the drug are highly effective in clearing enterococci from cardiac vegetations in rats (A. 
